CLASSIFICATION: GIP/GLP-1/GLUCAGON RECEPTOR TRIAGONIST
ACTIVE SUBSTANCE: RETATRUTIDE
FORM: 2 ML VIAL x 20 MG (LYOPHILIZED POWDER)
ACTIVE HALF-LIFE: ~ 6 DAYS
DOSAGE: 0.5 MG/WEEK
ACNE: NOT REPORTED
WATER RETENTION: NOT REPORTED
HIGH BLOOD PRESSURE (HBP): POSSIBLE
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: DRAGON PHARMA
Dragon Pharma proudly presents its premium Retatrutide 20 mg lyophilized powder, a cutting-edge peptide pharmaceutical engineered for the serious athlete and bodybuilder. As the newest frontier in metabolic enhancement, Retatrutide represents a significant leap beyond traditional GLP-1 agonists like Semaglutide and Tirzepatide. By simultaneously targeting the glucagon, GIP (glucose-dependent insulinotropic polypeptide), and GLP-1 (glucagon-like peptide-1) receptors, this triple-action compound orchestrates a powerful symphony of effects: profound appetite suppression, significantly enhanced calorie expenditure, and improved insulin sensitivity. Dragon Pharma's formulation ensures exceptional purity and potency in every 2 mL vial, providing researchers and fitness enthusiasts with a reliable tool for achieving unprecedented levels of leanness and metabolic optimization. Sourced and manufactured under strict quality control, this product is designed for those who demand nothing less than pharmaceutical-grade excellence in their pursuit of the ultimate physique.
The effects of Retatrutide are multifaceted, making it a versatile agent for body recomposition. Its primary and most notable action is potent appetite suppression, which is mediated through direct action on brain receptors that regulate hunger and satiety. This leads to a natural, effortless reduction in caloric intake, which is fundamental for cutting phases. Concurrently, Retatrutide increases thermogenesis and basal metabolic rate via its glucagon receptor activity, meaning the body burns more calories at rest. This dual-pathway approach—reducing energy in and increasing energy out—creates a powerful caloric deficit. Furthermore, its activity on GIP and GLP-1 receptors promotes improved glycemic control and insulin sensitivity, which helps partition nutrients towards muscle and away from fat storage. Users often report a significant reduction in visceral fat, sharper muscle definition, and a decrease in food cravings, particularly for high-calorie or sugary foods. According to a landmark study published in the New England Journal of Medicine, Retatrutide demonstrated substantial weight loss efficacy in clinical trials, underscoring its potential.
Dragon Pharma Retatrutide 20 mg is supplied as a sterile lyophilized powder that requires reconstitution with bacteriostatic water before subcutaneous injection. Due to its long half-life of approximately 5-7 days, dosing frequency is typically once per week, though some protocols may split the dose into twice-weekly administrations for more stable blood levels. For beginners, a starting dose of 2 mg per week is strongly recommended to assess individual tolerance. The dose can be gradually titrated upward by 1-2 mg every 4 weeks. The effective dose range for significant body recomposition is typically between 4 mg and 8 mg weekly. Advanced users or those with a higher tolerance may explore doses up to 10-12 mg per week, though this increases the risk of side effects. It is crucial to reconstitute the vial gently to avoid degrading the peptide, store the reconstituted solution in a refrigerator, and use it within the recommended timeframe. Always inject into clean, rotated subcutaneous sites like the abdomen or thigh.
Integrating Retatrutide into a structured cycle maximizes its benefits while preserving lean muscle mass. A standalone Retatrutide cycle of 8-12 weeks is effective for pure fat loss. However, for bodybuilders, combining it with other supportive compounds can yield synergistic results. During a cutting phase, Retatrutide's catabolic environment (via calorie deficit) can be counteracted by adding anabolic agents that promote nitrogen retention and muscle protein synthesis.
A sample 12-week cutting cycle could be: Weeks 1-12: Retatrutide (titrated from 2mg to 8mg/week) + Testabol 400 (400mg/week). Weeks 8-12: Masteron 200 (400mg/week). Follow with a 4-week PCT.
While Retatrutide is generally well-tolerated, users should be aware of potential side effects, most of which are dose-dependent and gastrointestinal in nature. The most common include nausea, vomiting, diarrhea, and constipation, especially during the dose-titration phase. These often subside as the body adapts over 1-2 weeks. Starting with a low dose and increasing slowly is the best mitigation strategy. Hypoglycemia is a possible risk, particularly when combined with other insulin-sensitizing compounds or in a fasted state; monitoring blood glucose and ensuring adequate carbohydrate intake around training is advised. As with any injectable, there is a risk of injection site reactions (redness, itching). Rare but more serious potential effects include acute pancreatitis and gallbladder issues. It is contraindicated for individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Hydration, a balanced electrolyte intake, and regular health monitoring are paramount.
Dragon Pharma's Retatrutide 20 mg is synthesized in state-of-the-art, ISO-certified laboratories using advanced peptide synthesis technology. Each batch undergoes rigorous third-party testing via High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry to verify peptide purity (consistently over 99%), amino acid sequence accuracy, and absence of microbial contamination. The lyophilization process ensures long-term stability and potency. Packaged in sterile, nitrogen-flushed vials with tamper-evident seals, Dragon Pharma guarantees that every product meets the highest standards of the research and performance community, providing peace of mind and predictable, reliable results.
Reconstitute the lyophilized powder with 1-2 mL of bacteriostatic water. Gently swirl the vial until the powder is fully dissolved. Do not shake vigorously, as this can damage the peptide structure. Once reconstituted, store the vial in a refrigerator (2-8°C or 36-46°F) and use it within 30 days to ensure potency and sterility.
Stacking is possible but requires extreme caution. Retatrutide's primary effects are appetite suppression and increased metabolic rate. Combining it with stimulant-based fat burners like Clenbuterol may compound side effects like tachycardia, anxiety, and blood pressure issues. A safer synergistic stack could include non-stimulant compounds like GW501516 (Cardarine) for endurance and lipid metabolism. Always start with low doses of each compound and monitor your body's response closely.
Semaglutide is a GLP-1 receptor agonist, Tirzepatide is a dual GIP and GLP-1 receptor agonist, while Retatrutide is a triple agonist adding glucagon receptor activity to the mix. The glucagon component is key—it increases energy expenditure and calorie burning more significantly than the other two. In essence, Retatrutide offers a three-pronged approach: suppressing appetite (GLP-1/GIP), improving insulin sensitivity (GIP/GLP-1), and directly boosting metabolism (glucagon), making it potentially more potent for weight loss and body recomposition.
No, a traditional PCT is not required after a cycle of Retatrutide alone, as it is not hormonally suppressive in the way that androgenic or anabolic steroids are. It does not directly inhibit the hypothalamic-pituitary-gonadal (HPG) axis. However, if Retatrutide was used as part of a stack with suppressive compounds like testosterone or SARMs, then a proper PCT (e.g., with Nolvadex or Enclomiphene) is absolutely necessary to restore natural hormone production.
Noticeable appetite suppression and reduced cravings can often be felt within the first 1-2 weeks of starting a low dose. Visible fat loss and changes in body composition typically become apparent after 4-6 weeks of consistent use at an effective dose, combined with a proper diet and training regimen. The most dramatic results are usually seen between weeks 8 and 12, as the dose is titrated to an optimal level and the cumulative metabolic effects take hold.
Please log in to write RETATRUTIDE 20 MG review.
CLASSIFICATION: GLP-1 RECEPTOR AGONIST
ACTIVE SUBSTANCE: SEMAGLUTIDE
FORM: 2 ML VIAL x 5 MG (LYOPHILIZED POWDER)
ACTIVE HALF-LIFE: ~7 DAYS
DOSAGE: 0.25 - 0.5 MG/WEEK
ACNE: NO
WATER RETENTION: NO
HIGH BLOOD PRESSURE (HBP): NO
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: DRAGON PHARMA, EUROPE
LABORATORY TESTED: VIEW LAB RESULTS
CLASSIFICATION: GIP/GLP-1/GLUCAGON RECEPTOR TRIAGONIST
ACTIVE SUBSTANCE: RETATRUTIDE
FORM: 2 ML VIAL x 10 MG (LYOPHILIZED POWDER)
ACTIVE HALF-LIFE: ~ 6 DAYS
DOSAGE: 0.5 MG/WEEK
ACNE: NOT REPORTED
WATER RETENTION: NOT REPORTED
HIGH BLOOD PRESSURE (HBP): POSSIBLE
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: DRAGON PHARMA
LABORATORY TESTED: VIEW LAB RESULTS
CLASSIFICATION: GLP-1 RECEPTOR AGONIST
ACTIVE SUBSTANCE: TIRZEPATIDE
FORM: 2 ML VIAL x 5 MG (LYOPHILIZED POWDER)
ACTIVE HALF-LIFE: ~5 DAYS
DOSAGE: 2.5 - 5 MG/WEEK (RESEARCH USE ONLY)
ACNE: NO
WATER RETENTION: NO
HIGH BLOOD PRESSURE (HBP): NO
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: DRAGON PHARMA, EUROPE
LABORATORY TESTED: VIEW LAB RESULTS
DUAL GLUCAGON AGONIST; GLP-1 AGONIST
ACTIVE SUBSTANCE: SURVODUTIDE
FORM: 2 ML VIAL x 10 MG (LYOPHILIZED POWDER)
ACTIVE HALF-LIFE: 109-115 HOURS
DOSAGE: MEN 0.6-4.8 MG/WEEK
ACNE: PERHAPS
WATER RETENTION: NO
HIGH BLOOD PRESSURE (HBP): NO
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: DRAGON PHARMA, EUROPE
LABORATORY TESTED: VIEW LAB RESULTS
DUAL GLUCAGON AGONIST; GLP-1 AGONIST
ACTIVE SUBSTANCE: MAZDUTIDE
FORM: 2 ML VIAL x 10 MG (LYOPHILIZED POWDER)
ACTIVE HALF-LIFE: 158-180 HOURS
DOSAGE: MEN 3-9 MG/WEEK
ACNE: NO
WATER RETENTION: NO
HIGH BLOOD PRESSURE (HBP): NO
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: DRAGON PHARMA, EUROPE
LABORATORY TESTED: VIEW LAB RESULTS